In a report released today, Hartaj Singh from Oppenheimer initiated coverage with a Buy rating on Inovio Pharmaceuticals (INO) and a price target of $35.00. The company’s shares closed last Thursday at $13.00.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 20.9% and a 50.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Vertex Pharmaceuticals, and Strongbridge Biopharma.
The word on The Street in general, suggests a Hold analyst consensus rating for Inovio Pharmaceuticals with a $16.14 average price target.
See today’s analyst top recommended stocks >>
Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $236.2K and net profit of $19.17 million. In comparison, last year the company earned revenue of $866.9K and had a GAAP net loss of $23.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Read More on INO:
